07:26:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaMid Cap Copenhagen
SektorHälsovård
IndustriLäkemedel & Handel
Veloxis Pharmaceuticals är ett läkemedelsbolag. Särskild specialisering återfinns inom behandlingen av organavstötning vid organtransplantationer. Visionen är att erbjuda läkemedel som underlättar absorptionen av läkemedel som fås oralt vid ingreppet. Bolaget innehar verksamhet på global nivå, främst inom Europa och Nordamerika. Veloxis Pharmaceuticals grundades 2002 och har sitt huvudkontor i Köpenhamn.

Kalender

2019-11-12 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-05-06 Kvartalsrapport 2019-Q1
2019-04-04 Ordinarie utdelning VELO 0.00 DKK
2019-04-03 Årsstämma 2018
2019-02-27 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-13 Kvartalsrapport 2018-Q2
2018-05-14 Kvartalsrapport 2018-Q1
2018-04-16 Ordinarie utdelning VELO 0.00 DKK
2018-04-13 Årsstämma 2017
2018-02-27 Bokslutskommuniké 2017
2017-11-14 Kvartalsrapport 2017-Q3
2017-08-16 Kvartalsrapport 2017-Q2
2017-05-16 Kvartalsrapport 2017-Q1
2017-04-10 Ordinarie utdelning VELO 0.00 DKK
2017-04-07 Årsstämma 2016
2017-02-28 Bokslutskommuniké 2016
2016-11-16 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-07-26 Extra Bolagsstämma 2016
2016-05-18 Kvartalsrapport 2016-Q1
2016-04-07 Ordinarie utdelning VELO 0.00 DKK
2016-04-06 Årsstämma 2015
2016-03-09 Bokslutskommuniké 2015
2015-11-11 Kvartalsrapport 2015-Q3
2015-08-26 Kvartalsrapport 2015-Q2
2015-05-20 Kvartalsrapport 2015-Q1
2015-03-27 Ordinarie utdelning VELO 0.00 DKK
2015-03-26 Årsstämma 2014
2015-03-03 Bokslutskommuniké 2014
2014-04-10 Ordinarie utdelning VELO 0.00 DKK
2013-04-18 Ordinarie utdelning VELO 0.00 DKK
2013-04-17 Årsstämma 2012
2012-04-19 Ordinarie utdelning VELO 0.00 DKK
2011-04-13 Ordinarie utdelning
2010-04-22 Ordinarie utdelning
2019-12-02 22:57:38

Company Release no. 19/2019

To: NASDAQ Copenhagen A/S                                                      

Copenhagen, Denmark, 2 December 2019


Veloxis Increases Share Capital in Connection with Exercise of Warrants


Veloxis Pharmaceuticals A/S announces that the Company's capital has been increased by 1,104,523 new shares with a nominal value of DKK 0.10 each corresponding to an increase of the share capital with nominally DKK 110,452.30 as a consequence of the exercise of warrants by current and former employees of the Company granted under the Company's warrant program.

As a result of the employee’s investment in the Company proceeds to Veloxis Pharmaceuticals A/S from the capital increase amount to DKK 1,228,630.52.

The subscription price for the new shares is DKK 0.86 per share of nominal DKK 0.10 (with regard to 283,332 shares), DKK 0.95 per share of nominal DKK 0.10 (with regard to 300,000 shares), DKK 1.01 per share of nominal DKK 0.10 (with regard to 224,582 shares), DKK 1.06 per share of nominal DKK 0.10 (with regard to 100,000 shares), DKK 1.12 per share of nominal DKK 0.10 (with regard to 44,444 shares), DKK 2.06 per share of nominal DKK 0.10 (with regard to 122,165 shares), and DKK 2.19 per share of nominal DKK 0.10 (with regard to 30,000 shares).

The new shares will be listed on NASDAQ Copenhagen following registration of the capital increase with the Danish Business Authority, upon which the share capital of Veloxis Pharmaceuticals A/S will be DKK 173,943,534 divided into shares of DKK 0.10 each.

Each share of nominal DKK 0.10 carries one vote at general meetings in Veloxis Pharmaceuticals A/S.  The new shares give rights to dividend and other rights from the time of registration of the capital increase with the Danish Business Authority.


For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.